The Potential of Antiviral Peptides as COVID-19 Therapeutics

@article{Mahendran2020ThePO,
  title={The Potential of Antiviral Peptides as COVID-19 Therapeutics},
  author={Aravindh Mahendran and Yin Sze Lim and Chee-Mun Fang and H. Loh and C. Le},
  journal={Frontiers in Pharmacology},
  year={2020},
  volume={11}
}
To date, more than 17 million cases of coronavirus disease 2019 (COVID-19) and 900,000 deaths have been reported globally (World Health Organization, 2020). Major collaborative efforts focusing on the development of anti-SARS-CoV-2 vaccines and antiviral therapeutics are accelerated at an unprecedented rate. Various therapeutic agents quickly taken into clinical trials are largely based on existing drugs with non-specific antiviral activities or compounds pharmacologically speculated to be… Expand

Figures from this paper

...
1
2
...

References

SHOWING 1-10 OF 46 REFERENCES
Multidrug treatment with nelfinavir and cepharanthine against COVID-19
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Antiviral peptides as promising therapeutic drugs
Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections
Human Antimicrobial Peptides as Therapeutics for Viral Infections
Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Perspective of Use of Antiviral Peptides against Influenza Virus
A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses
Enfuvirtide, the first fusion inhibitor to treat HIV infection.
...
1
2
3
4
5
...